Venlafaxine is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class.^[2][3][4] First introduced by Wyeth in 1993, now marketed by Pfizer, it is licensed for the treatment of major depressive disorder (MDD), as a treatment for generalized anxiety disorder, and comorbid indications in certain anxiety disorders with depression. In 2007, venlafaxine was the sixth most commonly prescribed antidepressant on the U.S. retail market,